ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) lost -5.66 Percent and closed its previous trading session at $4. The stock traded with the average Volume of 1.49 Million at the end of last session.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has the Market Capitalization of 570.32 Million. The Stock has its 52-week High of $7.88 and 52-Week Low of $3.90 and it touched its 52-week high on 04/27/17 and 52-Week Low on 12/06/17.
The company reported its last earnings Actual EPS of $-0.13/share. While, the analyst predicted that the company could provide an EPS of $-0.14/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.01/share which shows an Earnings Surprise of 7.1 Percent.
Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -10.36% where SMA50 and SMA200 are -21.58% and -32.94% respectively.
The company shows its Return on Assets (ROA) value of -62.8%. The Return on Equity (ROE) value stands at 88.2%. While it’s Return on Investment (ROI) value is 213.9%.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) currently has a Weekly Volatility of 6.81% percent while its Monthly Volatility is at 7.79% percent. While talking about Performance of the Stock, ZIOPHARM Oncology, Inc. currently has a Weekly performance of -12.85%, monthly performance percentage is -14.35 percent, Quarterly performance is -35.9 percent, 6 months performance shows a percent value of -30.43% and Yearly Performance is -41.78 percent.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.